Disease Overview：Bronchiectasis（BE）
Bronchiectasis is a chronic respiratory disorder characterized by irreversible dilation and distortion of the bronchial tree, typically resulting from recurrent infection, inflammation, or impaired mucociliary clearance. Common etiologies include post-infectious damage (e.g., following severe pneumonia or tuberculosis), cystic fibrosis, primary ciliary dyskinesia, and immunodeficiency disorders. Patients often present with persistent productive cough, recurrent pulmonary infections, hemoptysis, and progressive exertional dyspnea. Diagnosis relies on high-resolution computed tomography (HRCT), which demonstrates hallmark findings such as bronchial wall thickening, “signet-ring” appearance, and lack of normal bronchial tapering. Management is multidisciplinary—centered on airway clearance techniques, long-term antibiotic strategies (including macrolide prophylaxis or inhaled antibiotics), anti-inflammatory agents, and, in select cases, surgical resection or bronchoscopic interventions for localized disease.
China offers distinct advantages for bronchiectasis care: leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—boast internationally trained pulmonologists with extensive experience in complex airway diseases. Advanced diagnostics including ultra-low-dose HRCT, quantitative CT analysis, and molecular pathogen identification are routinely integrated into clinical workflows. Success rates for medical stabilization exceed 85% in refractory cases, and minimally invasive surgical outcomes align with global benchmarks. Crucially, treatment costs in China average 40–60% lower than in the US or Western Europe—without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities). As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with top-tier specialists, providing itemized, transparent pricing upfront, arranging visa support, accommodation, interpreter services, and post-treatment follow-up—all tailored to individual clinical and logistical needs.
Bronchiectasis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Bronchiectasis (Respiratory Medicine)
Non-Surgical / Conservative Management
*Target criteria:* Stable disease, ≤2 exacerbations/year, FEV₁ ≥50% predicted, no massive hemoptysis or refractory infection.
- •Airway Clearance Therapy
- Home oscillatory PEP device (e.g., Acapella®): ¥850–¥1,200 → $120–$170 USD
- •Antibiotics (Chronic Suppression)
- Azithromycin (3-month oral course): ¥380 → $54 USD
- •Exacerbation Management (Per Episode)
- IV ceftriaxone (5-day course): ¥420 → $60 USD - High-resolution CT (HRCT) re-evaluation: ¥680 → $96 USD
Surgical / Interventional Options
*Eligibility:* Localized disease (≤2 lobes), recurrent severe infections/hemoptysis despite ≥6 months optimal medical therapy, FEV₁ ≥40%, no active bronchial colonization with *Pseudomonas* or NTM.
- •Preoperative Workup (Mandatory)
- Contrast-enhanced HRCT + 3D reconstruction: ¥950 → $135 USD - Bronchoscopy with BAL for microbiology: ¥1,100 → $155 USD
- •Lobectomy (VATS or open)
- Post-op ICU stay (1–3 days): ¥1,800/day → $255 USD/day - Total estimated surgical package (incl. anesthesia, 5-day ward): ¥35,000–¥52,000 → $4,950–$7,350 USD
Special/Complex Condition Management
- •Massive Hemoptysis (>200 mL/24h)
- Includes angiography, coil embolization, ICU monitoring (24h).
- •NTM-associated Bronchiectasis
- 18-month multidrug regimen (clarithromycin + amikacin + ethambutol): ¥15,200 → $2,150 USD
- •Severe Comorbid COPD/Fibrosis
Quick Selection Guide
- •<40 years, localized disease, budget-conscious: Start with airway clearance + inhaled antibiotics ($120–$340 USD/month); avoid surgery unless BAE fails.
- •60+ years, bilateral disease, comorbid CHF/COPD: Prioritize azithromycin suppression + pulmonary rehab; surgery contraindicated—opt for BAE if hemoptysis occurs ($54 USD/month + $1,770 USD if needed).
- •Refractory infection, FEV₁ >60%, no comorbidities: VATS lobectomy offers best long-term control ($4,950–$7,350 USD one-time) with 5-year exacerbation reduction >70%.
- •NTM-positive, immunocompetent: Commit to full 18-month regimen ($2,150 USD total)—shorter courses risk resistance and relapse.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Bronchiectasis Medical Vacation Packages
Curated transparent all-inclusive packages combining Bronchiectasis treatment with China top medical destinations:
